CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Entheon Biomedical Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Entheon Biomedical Corp
Suite 720-999 W Broadway Street
Phone: (604) 562-3932p:604 562-3932 VANCOUVER, BC  V5Z 1K5  Canada Ticker: ENBIENBI
Business Summary
Entheon Biomedical Corp. is a Canada-based biotechnology research and development company. The Company is focused on treating addiction and substance-use disorders.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
11/30/202311/30/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Subsidiaries
Business Name Address City State/Province Country
Lobo Genetics Inc. 40 University Ave Toronto ON Canada

Business Names
Business Name
ENBI
HaluGen Life Sciences Inc
Lobo Genetics Inc.
MPV

General Information
Outstanding Shares: 8,858,934 (As of 4/18/2024)
Stock Exchange: CNQ
Fax Number: (514) 718-5998


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 23, 2024